Already a member?
Login
Become a member
Register
About
About PCSK9 Forum
Editorial Board
Mission Statement
Home
About PCSK9
What are PCSK9 inhibitors?
Why are new treatments needed?
Which patients may benefit?
Expert Meetings
News
News
Meeting Reports
Commentary
Hot topics
From the Editors
Expert views
Slides
Slide Resource Programme
Slides by Editorial Board
Trials
Videos
Resources
Trials
Slides by Editorial Board
Events
Videos
Webcasts
Guidelines & Consensus Guidance
Article Archive
Contact
⇒ Main Menu
About
– About PCSK9 Forum
– Editorial Board
– Mission Statement
– Home
– What are PCSK9 inhibitors?
– Why are new treatments needed?
– Which patients may benefit?
Expert Meetings
News
– News
– Meeting Reports
– Hot topics
– From the Editors
– Expert views
Slides
– Slide Resource Programme
– Slides by Editorial Board
Trials
Videos
Resources
– Trials
– Slides by Editorial Board
– Events
– Videos
– Webcasts
– Guidelines & Consensus Guidance
– Article Archive
Contact
News
Apo(a) size and PAD revascularisation outcomes: What’s the link?
Lepodisiran: What progress towards Lp(a) reduction?
Phase 1 data show sustained Lp(a) reduction with lepodisiran
Heart-1 trial: Interim data show PCSK9 gene editing lowers LDL-C
Small apoA isoforms linked to worse PAD revascularisation outcomes
OCEAN(a)-DOSE study highlights Lp(a) variability with time
Latest News Updates
PCSK9, FH and Lp(a)
Posted on
18 March 2014
|
Overview of FH
Prof Eric Brucket, France
The role of primary care in FH detection
Reduced costs with a national FH service
Alirocumab reduces Lp(a): pooled analysis
Lp(a), CVD risk and FH
Related content